Washington, DC 20006-5349
HELPLINE
Dr. Fred Hirsch, the CEO of the International Association for the Study of Lung Cancer (IASLC) and Professor at the University of Colorado School of…
In light of the newly released report by the Centers for Disease Control and Prevention (CDC) about the increase in mortality and morbidity of mesothelioma…
We are thrilled to announce that our executive director, Mary Hesdorffer, was selected as the recipient of the Gabriella Graham Patient Advocacy Award. This award…
Through partial funding by the Mesothelioma Applied Research Foundation, the National Comprehensive Cancer Network (NCCN) has published updated patient resources for malignant pleural mesothelioma. The…
The Meso Foundation announced today that at the end of this month, Dr. Lee Krug’s term on the Board of Directors (BOD) of the Mesothelioma…
Melissa Culligan, a member of the Mesothelioma Applied Research Foundation’s Board of Directors started her work on Saturday, December 3 at the 17th World Conference…
Results from studies using PDL1 inhibitors Today, at the World Conference on Lung Cancer 2016 (Mesothelioma Track), several investigators presented data for their immunotherapy studies.…
“Mesothelioma is known as a traditionally under-funded and under-studied cancer.” That’s the answer customarily given to patients, their families, and the public at large when…
This week, representatives of the Mesothelioma Applied Research Foundation are attending one of the largest medical conferences in the world: the World Conference on Lung…
by Marcia Schekel A diagnosis … mesothelioma … a punch to the gut … frozen with fear. Mine was April 2014: surgical biopsy, pleural mesothelioma…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
